Everything You Need to Know About Anticoagulants (heparin, warfarin, DOACs) for Step 1

Anticoagulants are the kind of Step 1 topic where you can feel “good” about the mechanism but still miss questions because the exam tests clinical logic: Which drug works fastest? Which one affects PT vs PTT? Which one is safe in pregnancy? Which one has HIT? If you can organize heparin, warfarin, and the DOACs into a single coag cascade mental model—then map each drug to labs, reversal, and classic adverse effects—you’ll pick up a lot of easy points.

---

Big Picture: What Are Anticoagulants Doing?

Anticoagulants prevent clot propagation (they don’t “melt” existing clots—that’s thrombolytics like tPA). They mainly target the coagulation cascade (secondary hemostasis), especially thrombin (IIa) and factor Xa, because those are the biggest amplification steps.

Coagulation cascade: the Step 1 frame

• Extrinsic pathway: Factor VII → measured by PT/INR
• Intrinsic pathway: Factors XII, XI, IX, VIII → measured by PTT
• Common pathway: X → II (thrombin) → I (fibrin)

High-yield:

• PTT tracks heparin effect
• PT/INR tracks warfarin effect
• DOACs often don’t require routine lab monitoring (Step 1 loves this)

---

When Do We Anticoagulate? (Clinical Presentations You’ll See)

Classic Step-style scenarios:

• DVT/PE: unilateral leg swelling + pleuritic chest pain, tachycardia, hypoxemia
• Atrial fibrillation: stroke prevention (embolus from left atrial appendage)
• Mechanical heart valves: long-term anticoagulation (warfarin is classic)
• Acute coronary syndromes: heparin used in hospital management (often alongside antiplatelets)

Important distinction:

• Venous clots (DVT/PE): fibrin/RBC-rich → target coagulation
• Arterial clots (MI, stroke): platelet-rich → antiplatelets are central, but anticoagulants can be adjuncts depending on setting

---

Quick Comparison Table (Mechanism, Labs, Reversal, High-Yield Toxicities)

First Aid cross-reference: Cardiovascular Pharmacology → Anticoagulants (heparin, warfarin, direct Xa/IIa inhibitors) + Hematology → Coagulation cascade & labs (PT/PTT).

---

Heparin (Unfractionated): The “Fast” Anticoagulant

Definition & mechanism

Heparin potentiates antithrombin, which inactivates:

• Thrombin (IIa)
• Factor Xa (and also IXa, XIa, XIIa)

Why it’s fast: It works by accelerating an existing inhibitor (antithrombin), so the effect is immediate when given IV.

Pathophysiology tie-in (why PTT?)

UFH inhibits factors of the intrinsic/common pathways enough to prolong PTT (intrinsic + common).

Clinical uses (Step 1 high-yield)

• Initial treatment of DVT/PE
• Acute coronary syndromes
• Bridging to warfarin for rapid anticoagulation (more on bridging below)
• Safe in pregnancy (does not cross placenta)

Diagnosis/monitoring

• Monitor PTT (especially UFH, since it’s less predictable than LMWH)
• Platelet monitoring if concern for HIT

Adverse effects

• Bleeding
• Heparin-induced thrombocytopenia (HIT) (very high-yield)
• Osteoporosis with long-term use (classic board fact)

Antidote

• Protamine sulfate (positively charged) binds negatively charged heparin.

---

Heparin-Induced Thrombocytopenia (HIT): The Clotting Paradox

What it is (definition)

An immune-mediated reaction where heparin exposure leads to antibodies against the heparin–platelet factor 4 (PF4) complex, causing platelet activation → thrombosis despite thrombocytopenia.

Classic presentation (Step vignette)

• Recent heparin exposure (often 5–10 days after starting; can be sooner with prior exposure)
• Platelets drop (often >50% from baseline)
• New thrombosis (DVT/PE, limb ischemia)
• Skin necrosis at injection sites can occur

What to do

1. Stop all heparin (including flushes)
2. Start a non-heparin anticoagulant, classically:
   • Direct thrombin inhibitor: argatroban or bivalirudin
   • (Fondaparinux may be used in practice; Step 1 often emphasizes argatroban/bivalirudin)

High-yield trap:

• Do NOT start warfarin alone in acute HIT (can worsen hypercoagulability and risk skin necrosis).

First Aid cross-reference: HIT is typically highlighted under anticoagulant adverse effects and often reappears in hematology/immunology contexts.

---

LMWH (Enoxaparin): More Predictable Heparin

What changes vs UFH?

• Still works via antithrombin
• Preferentially inhibits factor Xa (less IIa activity than UFH)
• More predictable pharmacokinetics → less monitoring

Step 1 uses

• DVT prophylaxis post-op
• Treatment of DVT/PE
• Pregnancy-safe option

Antidote nuance

• Protamine reverses LMWH partially (classic nuance).

---

Warfarin: The “Vitamin K” Anticoagulant

Definition & mechanism

Warfarin inhibits vitamin K epoxide reductase in the liver → decreased $\gamma$-carboxylation of vitamin K–dependent clotting factors:

• II, VII, IX, X
• plus the natural anticoagulants protein C and protein S

Mnemonic: “1972 + C/S” (or “2, 7, 9, 10”).

Pathophysiology tie-in: Why PT/INR?

Factor VII has a short half-life and is in the extrinsic pathway → warfarin’s effect shows up as:

• Increased PT, monitored by INR

The delayed effect (and why bridging exists)

Warfarin takes days because it affects synthesis of new factors, not activity of existing ones.

Bridging concept (high-yield):

• Warfarin initially drops protein C (short half-life) faster than procoagulant factors → transient hypercoagulable state
• So in acute thrombosis, start heparin first, then overlap with warfarin until INR is therapeutic.

Clinical uses

• Long-term anticoagulation for:
  • Atrial fibrillation (depending on context; DOACs often preferred now, but warfarin still tested)
  • Mechanical heart valves (very classic warfarin indication)
  • DVT/PE long-term prevention (historically; DOACs increasingly used)

Warfarin adverse effects (must-know)

• Bleeding
• Skin necrosis (classically early after initiation; associated with protein C deficiency)
• Teratogenicity:
  • Warfarin crosses placenta → fetal abnormalities (“warfarin embryopathy”)
  • Heparin/LMWH are preferred in pregnancy

Reversal (exam favorite)

Depends on urgency:

• Non-urgent: Vitamin K
• Serious bleeding or need immediate reversal:
  • Prothrombin complex concentrate (PCC) (fast, concentrated factors)
  • ± Fresh frozen plasma (FFP) (more volume; used if PCC unavailable)

First Aid cross-reference: Warfarin mechanism, PT/INR, teratogenicity, skin necrosis appear prominently in cardiovascular pharm.

---

DOACs: Direct Oral Anticoagulants (Fast, Convenient, No Routine Labs)

Core idea

DOACs directly inhibit a single activated clotting factor:

• Dabigatran → direct thrombin (IIa) inhibitor
• Apixaban, rivaroxaban, edoxaban → direct factor Xa inhibitors

Why Step 1 cares

• Rapid onset
• No routine monitoring (contrast with heparin/warfarin)
• Commonly used for:
  • Nonvalvular atrial fibrillation stroke prevention
  • DVT/PE treatment and prevention

Reversal agents (high-yield)

• Dabigatran → idarucizumab
• Factor Xa inhibitors → andexanet alfa
  (Some curricula also mention PCC as an alternative in major bleeding.)

Adverse effects

• Bleeding (the main one to know)
• Dabigatran: GI symptoms are commonly tested

First Aid cross-reference: Direct Xa and IIa inhibitors are usually listed under anticoagulants in cardiovascular pharmacology with antidotes noted in updated editions.

---

How They Show Up on Step: Pattern Recognition

1) “Which lab changes?”

• Heparin → ↑ PTT
• Warfarin → ↑ PT/INR
• DOACs → no routine monitoring

2) “Pregnant patient needs anticoagulation”

• Use heparin or LMWH
• Avoid warfarin (teratogen)

3) “Patient develops thrombocytopenia + thrombosis on heparin”

• Think HIT
• Stop heparin; start argatroban/bivalirudin

4) “Starting warfarin causes skin necrosis”

• Due to protein C depletion
• More likely in protein C deficiency
• Bridge with heparin when appropriate

5) “Need reversal now”

• Heparin → protamine sulfate
• Warfarin → vitamin K (slow), PCC (fast) ± FFP
• Dabigatran → idarucizumab
• Xa inhibitors → andexanet alfa (or PCC)

---

Rapid-Fire High-Yield Facts (Last-Minute Review)

• Heparin: activates antithrombin → inhibits IIa + Xa; PTT; reversed by protamine; causes HIT.
• LMWH: more anti-Xa than anti-IIa; minimal monitoring; partial protamine reversal; safer profile than UFH.
• Warfarin: inhibits vitamin K epoxide reductase → ↓ II, VII, IX, X, C, S; PT/INR; teratogen; skin necrosis; reversed by vit K and PCC.
• DOACs:
  • Dabigatran (IIa) → idarucizumab
  • Apixaban/rivaroxaban/edoxaban (Xa) → andexanet alfa
  • No routine monitoring; bleeding is main toxicity.

---

Mini Self-Check (3 Common Step Prompts)

1. You’re asked to anticoagulate a pregnant patient with DVT.
   Pick: LMWH (enoxaparin) or UFH.

2. A hospitalized patient on heparin has platelets fall from 240k to 90k and develops a new DVT.
   Diagnosis: HIT → treat with argatroban (or bivalirudin), not warfarin alone.

3. A patient on warfarin has a life-threatening GI bleed and needs rapid reversal.
   Treatment: PCC (fast) + vitamin K (sustained) ± FFP.